PRESS RELEASE published on 10/24/2024 at 07:36, 1 year 6 months ago ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA ONWARD® Medical raises EUR 50 million with strategic investment from Ottobock SE & Co. KGaA, extending cash runway. Ottobock acquires c.10% share capital, initiating collaboration for spinal cord injury therapies Investment EUR 50 Million ONWARD Medical Ottobock SE & Co. KGaA Spinal Cord Injury Therapies
BRIEF published on 10/22/2024 at 17:57, 1 year 7 months ago ONWARD Medical lance une augmentation de capital de 40 millions d'euros avec la participation d'Ottobock Placement Privé Augmentation De Capital ONWARD Medical Investissement Ottobock Thérapie De La Colonne Vertébrale
BRIEF published on 10/22/2024 at 17:57, 1 year 7 months ago ONWARD Medical Initiates €40 Million Capital Increase with Ottobock's Involvement Private Placement Capital Increase ONWARD Medical Ottobock Investment Spinal Therapy
PRESS RELEASE published on 10/22/2024 at 17:52, 1 year 7 months ago ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA ONWARD Medical launches capital increase of c. EUR 40 million with EUR 22.5 million cornerstone investment from Ottobock SE & Co. KGaA, aiming to develop spinal cord stimulation therapies for spinal cord injury patients Capital Increase Ottobock ONWARD Medical EUR 40 Million Spinal Cord Stimulation
BRIEF published on 10/15/2024 at 07:38, 1 year 7 months ago ONWARD Medical obtient les droits exclusifs de la technologie BCI WIMAGINE ONWARD Medical BCI WIMAGINE Système ARC-BCI Paralysie Interface Cerveau-machine
BRIEF published on 10/15/2024 at 07:38, 1 year 7 months ago ONWARD Medical obtains exclusive rights to WIMAGINE BCI technology ONWARD Medical BCI WIMAGINE ARC-BCI System Paralysis Brain-machine Interface
PRESS RELEASE published on 10/15/2024 at 07:33, 1 year 7 months ago ONWARD® Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d’interface cerveau machine (BCI) WIMAGINE® de Clinatec ONWARD Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d'interface cerveau machine WIMAGINE de Clinatec, visant à restaurer les mouvements guidés par la pensée après une paralysie Technologie CEA ONWARD Medical Interface Cerveau Machine WIMAGINE
Published on 05/23/2026 at 19:45, 5 hours 1 minute ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 21 hours 31 minutes ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 21 hours 46 minutes ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 22 hours 21 minutes ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 22 hours 21 minutes ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/23/2026 at 16:30, 8 hours 15 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 8 hours 49 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 2 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 22:05, 1 day 2 hours ago Abivax Presents Q1 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with UC
Published on 05/22/2026 at 19:51, 1 day 4 hours ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/22/2026 at 19:35, 1 day 5 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 6 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 6 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 11 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 11 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026